Search research articles
Contact Us
Filters
Showing results (81-90 of 167) with videos related to
Page
of 17
Sort By:
Canadian Journal of Public Health = Revue Canadienne De Sante Publique
|
July 18, 2023
"When I think about my future, I just see darkness": How youth exiting homelessness navigate the hazy, liminal space between socioeconomic exclusion and inclusion
Naomi S Thulien, Stephen W Hwang, Nicole Kozloff, et al.
Pancreas
|
December 20, 2019
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
Teresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
September 15, 2010
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Richard Eastell, Claus Christiansen, Andreas Grauer, et al.
Journal of Pancreatic Cancer
|
March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Mark H O'Hara, Wells Messersmith, Hedy Kindler, et al.
Investigational New Drugs
|
March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
March 10, 2017
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension
Nelson B Watts, Jacques P Brown, Socrates Papapoulos, et al.
Cephalalgia : an International Journal of Headache
|
November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Messoud Ashina, David Kudrow, Uwe Reuter, et al.
Investigational New Drugs
|
December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin, Susan E Minton, Patricia M LoRusso, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
July 23, 2013
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk
Elizabeth J Samelson, Paul D Miller, Claus Christiansen, et al.
JOP : Journal of the Pancreas
|
September 12, 2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma
Parvin F Peddi, Sam Lubner, Robert McWilliams, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 167) with videos related to
Sort By:
Page
of 17
Canadian Journal of Public Health = Revue Canadienne De Sante Publique
|
July 18, 2023
"When I think about my future, I just see darkness": How youth exiting homelessness navigate the hazy, liminal space between socioeconomic exclusion and inclusion
Naomi S Thulien, Stephen W Hwang, Nicole Kozloff, et al.
Pancreas
|
December 20, 2019
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
Teresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
September 15, 2010
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
Richard Eastell, Claus Christiansen, Andreas Grauer, et al.
Journal of Pancreatic Cancer
|
March 29, 2020
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors
Mark H O'Hara, Wells Messersmith, Hedy Kindler, et al.
Investigational New Drugs
|
March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
Katrina S Pedersen, Patrick M Grierson, Joel Picus, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
March 10, 2017
Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension
Nelson B Watts, Jacques P Brown, Socrates Papapoulos, et al.
Cephalalgia : an International Journal of Headache
|
November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions
Messoud Ashina, David Kudrow, Uwe Reuter, et al.
Investigational New Drugs
|
December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin, Susan E Minton, Patricia M LoRusso, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
July 23, 2013
RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk
Elizabeth J Samelson, Paul D Miller, Claus Christiansen, et al.
JOP : Journal of the Pancreas
|
September 12, 2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma
Parvin F Peddi, Sam Lubner, Robert McWilliams, et al.
Page
of 17